Cargando…

A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation

BACKGROUND: Evolving practices in non-small cell lung cancer (NSCLC) therapy inevitably affect health care budgets, especially through the introduction of targeted therapies. This results in a rise of health economic evaluations (HEEs) in this domain. This article reviews the quality of the economic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jie, Du, Shuzhang, Zhu, Yumei, Liang, Yan, Lu, Jingli, Chang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293415/ https://www.ncbi.nlm.nih.gov/pubmed/32606931 http://dx.doi.org/10.2147/CMAR.S248471

Ejemplares similares

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist
por: Yang, Yongjie, et al.
Publicado: (2021)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
por: Moriwaki, Kensuke, et al.
Publicado: (2021)

Evaluation of the reporting quality of clinical practice guidelines on prostate cancer using the RIGHT checklist
por: Liu, Kefeng, et al.
Publicado: (2021)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
por: Fang, Rui, et al.
Publicado: (2018)

Evaluation of the reporting quality of clinical practice guidelines on gliomas using the RIGHT checklist
por: Yang, Yongjie, et al.
Publicado: (2021)

Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes
por: Pawełczyk, Konrad, et al.
Publicado: (2016)

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan
por: Fathinul, F, et al.
Publicado: (2014)

Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
por: Wu, Yanyu, et al.
Publicado: (2022)

Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea
por: Lim, Eun-A, et al.
Publicado: (2016)

Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist
por: Yang, Yongjie, et al.
Publicado: (2021)

A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis
por: Gong, Jing, et al.
Publicado: (2018)

Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines
por: Geroy, Lester Sam Araneta
Publicado: (2012)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

First-line management of metastatic non-small cell lung cancer: An Indian perspective
por: Ghadyalpatil, Nikhil Suresh, et al.
Publicado: (2019)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
por: Tremblay, Gabriel, et al.
Publicado: (2016)

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
por: Lange, Ansgar, et al.
Publicado: (2014)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
por: Graham, Donna M., et al.
Publicado: (2014)

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Sama, Srikar, et al.
Publicado: (2022)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
por: Li, Wei, et al.
Publicado: (2022)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer
por: Belaidi, Lahcene, et al.
Publicado: (2023)

Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
por: Schuette, Wolfgang, et al.
Publicado: (2012)

Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist
por: Zhang, Qiwen, et al.
Publicado: (2021)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
por: Wu, Bin, et al.
Publicado: (2012)

First-Line Therapy for Metastatic Non–Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches
por: Bauml, Joshua, et al.
Publicado: (2020)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
por: Loong, Herbert H., et al.
Publicado: (2022)

Evaluating Characteristics in Lung Cancer Screening Program Participants and Non-Small Cell Lung Cancer (NSCLC) Patient Populations
por: Khan, Iftekhar, et al.
Publicado: (2022)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2u06g4javcfcpp28o4qcsbs9i1